327 related articles for article (PubMed ID: 9242556)
1. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
2. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
[TBL] [Abstract][Full Text] [Related]
3. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
4. PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease.
Nirmala K; Rajalekshmy KR; Raman SG; Shanta V; Rajkumar T
Leuk Res; 2002 Apr; 26(4):335-43. PubMed ID: 11839375
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
[TBL] [Abstract][Full Text] [Related]
7. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
8. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct 'end-stage' recombinations: implications for minimal residual disease monitoring.
Szczepański T; Langerak AW; Willemse MJ; Wolvers-Tettero IL; van Wering ER; van Dongen JJ
Leukemia; 2000 Jul; 14(7):1208-14. PubMed ID: 10914544
[TBL] [Abstract][Full Text] [Related]
11. Detection of T cell receptor delta gene rearrangements in childhood B and T lineage acute lymphoblastic leukaemia by southern blot and PCR: technical comparison of two methods of analysis.
Valetto A; Di Martino D; Scuderi F; Lanza T; Lanciotti M; Bottini F; Dini G
Clin Lab Haematol; 2000 Oct; 22(5):263-9. PubMed ID: 11122266
[TBL] [Abstract][Full Text] [Related]
12. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
14. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
Scholten C; Födinger M; Mitterbauer M; Laczika K; Mitterbauer G; Haas OA; Knöbl P; Schwarzinger I; Thalhammer R; Purtscher B
Ann Hematol; 1995 Oct; 71(4):155-60. PubMed ID: 7578520
[TBL] [Abstract][Full Text] [Related]
16. [The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Tutor-Ureta O; Díaz MA; Algara P; Madero L; Martínez P
Med Clin (Barc); 1999 Jul; 113(4):129-31. PubMed ID: 10472597
[TBL] [Abstract][Full Text] [Related]
17. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
18. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
[TBL] [Abstract][Full Text] [Related]
20. T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Mantadakis E; Danilatou V; Stiakaki E; Paterakis G; Papadhimitriou S; Kalmanti M
Pediatr Blood Cancer; 2007 Mar; 48(3):354-7. PubMed ID: 16206214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
